Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

If Bipolar Disorder Is Over-Diagnosed, What Are The Actual Diagnoses?
A year ago, a study by Rhode Island Hospital and Brown University researchers reported that fewer than half the patients previously diagnosed with bipolar disorder received an actual diagnosis of bipolar disorder after using a comprehensive, psychiatric diagnostic interview tool -- the Structured Clinical Interview for DSM-IV (SCID). In this follow-up study, the researchers have determined the actual diagnoses of those patients. Their study is published in the July 28 ahead of print online edition of The Journal of Clinical Psychiatry.
generic viagra online
Insurers 'Spinning' Some Data To Shape Reform
Insurers sometimes cherry-pick facts to make their case against certain aspects of reform efforts, including a public plan, The Washington Post reports.
News of the day
FDA Approves ADCIRCA(TM) (Tadalafil) Tablets For The Treatment Of Pulmonary Arterial Hypertension
United Therapeutics Corporation (Nasdaq: UTHR) announced that the United States Food and Drug Administration (FDA) has approved ADCIRCA(TM) (tadalafil) tablets for oral administration, with a recommended dose of 40 mg, as the first once-daily phosphodiesterase type 5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension (PAH). ADCIRCA is indicated to improve exercise ability in WHO Group I PAH patients, which encompasses patients with multiple forms of PAH including etiologies such as idiopathic and familial PAH as well as PAH associated with scleroderma and congenital heart disease.
Mental Health

Kohl Bill Would Save Consumers $3.5 Billion Per Year, According To FTC, USA

U.S. Senator Herb Kohl released the following statement on the announcement from U.S. Federal Trade Commission Chairman Jon Leibowitz that banning pay-for-delay settlements that keep generic drugs off the market would save consumers at least $3.5 billion per year and provide significant cost savings for federal government, which pays approximately one-third of all prescription drug costs. Senator Kohl"s bill, the Preserve Access to Affordable Generic Drugs Act (S. 369), would prohibit the anti-consumer practice of brand-name drug manufacturers using pay-off agreements to keep cheaper generic equivalents off the market. Introduced in February with Senators Chuck Grassley (R-IA), Russ Feingold (D-WI), Dick Durbin (D-IL) and Amy Klobuchar (D-MN), the bill is scheduled to be marked up by the Senate Judiciary Committee. "This morning, FTC Chairman Jon Leibowitz announced that putting an end to pay-for-delay deals between drug companies would save Americans $3.5 billion a year. These payoffs create an excessive and unreasonable barrier to the drug treatments people need by allowing brand pharmaceutical companies to pay off their generic competition to keep them out of the market. We cannot profess to care about the high cost of prescription drugs, while turning a blind eye to anti-competitive backroom deals between brand and generic drug companies that only serve the companies involved. I urge my colleagues to support my legislation to ban these settlements once and for all." Special Committee on Aging Senator Herb Kohl, Chair


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009